scholarly journals Is there a case for inclusion of medicines used to manage alcohol use disorder in the World Health Organization Model List of Essential Medicines?

2021 ◽  
Vol 63 (3) ◽  
pp. 297
Author(s):  
YatanPal Singh Balhara ◽  
Jatin Tarwani
Keyword(s):  
Alcohol Use ◽  
World Health Organization ◽  
Alcohol Use Disorder ◽  
Essential Medicines ◽  
World Health ◽  
Organization Model ◽  
The World ◽  
Health Organization

scholarly journals A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename)

2013 ◽  
Vol 89 (2) ◽  
pp. 171-178
Author(s):  
Helena Lutéscia L. Coelho ◽  
Luís Carlos Rey ◽  
Marina S.G. de Medeiros ◽  
Ronaldo A. Barbosa ◽  
Said G. da Cruz Fonseca ◽  
...  
Keyword(s):  
World Health Organization ◽  
Essential Medicines ◽  
World Health ◽  
Critical Comparison ◽  
The World ◽  
Health Organization ◽  
Medicines For Children

Persisting pain in childhood medical illness

2013 ◽  
pp. 319-327
Author(s):  
Martha Mherekumombe ◽  
John J. Collins
Keyword(s):  
Pain Management ◽  
World Health Organization ◽  
Essential Medicines ◽  
World Health ◽  
Medical Illness ◽  
Global Problem ◽  
The World ◽  
Health Organization ◽  
Medicines For Children

Persisting pain in the context of medical illness has been recognized recently as a global problem by the World Health Organization (WHO, 2012). Whilst the epidemiology of medical illness varies throughout the world, the general principles of pain management are applicable to most medical illnesses in children and are effective. Successful pain management for most children is contingent on the availability of the WHO model list of essential medicines for children (WHO, 2011), although regrettably not all medicines are available in every country in the world.

scholarly journals A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename)

2013 ◽  
Vol 89 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Helena Lutéscia L. Coelho ◽  
Luís Carlos Rey ◽  
Marina S.G. de Medeiros ◽  
Ronaldo A. Barbosa ◽  
Said G. da Cruz Fonseca ◽  
...  
Keyword(s):  
World Health Organization ◽  
Essential Medicines ◽  
World Health ◽  
Critical Comparison ◽  
The World ◽  
Health Organization ◽  
Medicines For Children

scholarly journals Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System

Pharmaceutics ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 567 ◽  
Author(s):  
Jose-Manuel delMoral-Sanchez ◽  
Isabel Gonzalez-Alvarez ◽  
Marta Gonzalez-Alvarez ◽  
Andres Navarro ◽  
Marival Bermejo
Keyword(s):  
World Health Organization ◽  
Classification System ◽  
Biopharmaceutics Classification System ◽  
Essential Medicines ◽  
World Health ◽  
Oral Drug ◽  
Essential Medicines List ◽  
The World ◽  
Health Organization ◽  
Biopharmaceutics Classification

The objective was using the Essential Medicines List for children by the World Health Organization (WHO) to create a pediatric biopharmaceutics classification system (pBCS) of the oral drugs included in the Essential Medicines List by the World Health Organization and to compare our results with the BCS for adults (aBCS). Several methods to estimate the oral drug dose in different pediatric groups were used to calculate dose number (Do) and solubility (high/low). The estimation of the gastrointestinal water volume was adapted to each pediatric group. Provisional permeability classification was done by comparison of each drug lipophilicity versus metoprolol as the model drug of high permeability. As a result, 24.5% of the included drugs moved from the favorable to unfavorable class (i.e., from high to low solubility). Observed changes point out potential differences in product performance in pediatrics compared to adults, due to changes in the limiting factors for absorption. BCS Class Changes 1 to 2 or 3 to 4 are indicative of drugs that could be more sensitive to the choice of appropriate excipient in the development process. Validating a pBCS for each age group would provide a valuable tool to apply in specific pediatric formulation design by reducing time and costs and avoiding unnecessary pediatric experiments restricted due to ethical reasons. Additionally, pBCS could minimize the associated risks to the use of adult medicines or pharmaceutical compound formulations.

Sign in / Sign up

Export Citation Format

Share Document